Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746633 | 0.92 | — | — | |
| SCHEMBL18636575 | 0.85 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL6534869 | 0.84 | STING1 (0.33) | — | |
| SCHEMBL14524031 | 0.83 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL3457655 | 0.82 | EPHX2 (0.33) | MAOAMAOB | |
| Hydrochloric Acid SCHEMBL6840669 | 0.82 | MEN1 (0.34) | — | |
| SCHEMBL8019850 | 0.80 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL19016239 | 0.80 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL18760237 | 0.79 | TDP1 (0.35) | — | |
| SCHEMBL12791563 | 0.78 | KMT2A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142977-A1 | GADOLINIUM-BASED CONTRAST AGENTS FOR SENSITIVE DETECTION OF Zn2+ WITH MRI | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-16 | — | — | US | disclosed |
| US-10207013-B2 | Gadolinium-based contrast agents for sensitive detection of Zn2+ with MRI | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170106103-A1 | NEW GADOLINIUM-BASED CONTRAST AGENTS FOR SENSITIVE DETECTION OF Zn2+ WITH MRI | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142977-A1 | GADOLINIUM-BASED CONTRAST AGENTS FOR SENSITIVE DETECTION OF Zn2+ WITH MRI | SLC30A6, SLC30A7, SLC39A11 | MAOA 2324/4885MAOB 2028/4885 |
| US-10207013-B2 | Gadolinium-based contrast agents for sensitive detection of Zn2+ with MRI | SLC30A6, SLC30A7, SLC39A11 | MAOA 2324/4885MAOB 2028/4885 |
| US-20170106103-A1 | NEW GADOLINIUM-BASED CONTRAST AGENTS FOR SENSITIVE DETECTION OF Zn2+ WITH MRI | SLC30A6, SLC30A7, SLC39A11 | MAOA 2532/4885MAOB 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.